

Age: 43  
Fasting: Y

FASTING: YES

### ▲ FSH AND LH

Analyte	Value	
▲ FSH	11.8 H	Reference Range: 1.6-8.0 mIU/mL
LH	7.7	Reference Range: 1.5-9.3 mIU/mL

### ▲ LIPID PANEL, STANDARD

Analyte	Value	
▲ CHOLESTEROL, TOTAL	202 H	Reference Range: <200 mg/dL
HDL CHOLESTEROL	56	Reference Range: > OR = 40 mg/dL
TRIGLYCERIDES	61	Reference Range: <150 mg/dL
▲ LDL-CHOLESTEROL	131 H	mg/dL (calc)
Reference range: <100		
Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors.		
LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 ( <a href="http://education.QuestDiagnostics.com/faq/FAQ164">http://education.QuestDiagnostics.com/faq/FAQ164</a> )		
CHOL/HDLC RATIO	3.6	Reference Range: <5.0 (calc)
▲ NON HDL CHOLESTEROL	146 H	Reference Range: <130 mg/dL (calc)
For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.		

### ▲ COMPREHENSIVE METABOLIC PANEL

Analyte	Value	
GLUCOSE	90	Reference Range: 65-99 mg/dL
Fasting reference interval		
UREA NITROGEN (BUN)	11	Reference Range: 7-25 mg/dL
CREATININE	0.97	Reference Range: 0.60-1.29 mg/dL
EGFR	99	Reference Range: > OR = 60 mL/min/1.73m <sup>2</sup>
The eGFR is based on the CKD-EPI 2021 equation. To calculate the new eGFR from a previous Creatinine or Cystatin C result, go to <a href="https://www.kidney.org/professionals/kdoqi/gfr%5Fcalculator">https://www.kidney.org/professionals/kdoqi/gfr%5Fcalculator</a>		
BUN/CREATININE RATIO	NOT APPLICABLE	Reference Range: 6-22 (calc)

SODIUM	139	Reference Range: 135-146 mmol/L
POTASSIUM	3.7	Reference Range: 3.5-5.3 mmol/L
CHLORIDE	99	Reference Range: 98-110 mmol/L
CARBON DIOXIDE	29	Reference Range: 20-32 mmol/L
CALCIUM	9.8	Reference Range: 8.6-10.3 mg/dL
PROTEIN, TOTAL	7.5	Reference Range: 6.1-8.1 g/dL
▲ ALBUMIN	5.3 H	Reference Range: 3.6-5.1 g/dL
GLOBULIN	2.2	Reference Range: 1.9-3.7 g/dL (calc)
ALBUMIN/GLOBULIN RATIO	2.4	Reference Range: 1.0-2.5 (calc)
BILIRUBIN, TOTAL	1.1	Reference Range: 0.2-1.2 mg/dL
ALKALINE PHOSPHATASE	47	Reference Range: 36-130 U/L
AST	14	Reference Range: 10-40 U/L
ALT	18	Reference Range: 9-46 U/L

#### ▲ CBC (INCLUDES DIFF/PLT)

Analyte	Value	
WHITE BLOOD CELL COUNT	5.7	Reference Range: 3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT	5.38	Reference Range: 4.20-5.80 Million/uL
HEMOGLOBIN	17.1	Reference Range: 13.2-17.1 g/dL
HEMATOCRIT	50.0	Reference Range: 38.5-50.0 %
MCV	92.9	Reference Range: 80.0-100.0 fL
MCH	31.8	Reference Range: 27.0-33.0 pg
MCHC	34.2	Reference Range: 32.0-36.0 g/dL
RDW	11.6	Reference Range: 11.0-15.0 %
PLATELET COUNT	223	Reference Range: 140-400 Thousand/uL
MPV	10.4	Reference Range: 7.5-12.5 fL
ABSOLUTE NEUTROPHILS	3762	Reference Range: 1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES	1454	Reference Range: 850-3900 cells/uL
ABSOLUTE MONOCYTES	456	Reference Range: 200-950 cells/uL
▲ ABSOLUTE EOSINOPHILS	11 L	Reference Range: 15-500 cells/uL
ABSOLUTE BASOPHILS	17	Reference Range: 0-200 cells/uL
NEUTROPHILS	66	%
LYMPHOCYTES	25.5	%
MONOCYTES	8.0	%
EOSINOPHILS	0.2	%
BASOPHILS	0.3	%

#### ▲ ESTRADIOL,ULTRASENSITIVE, LC/MS

Analyte	Value
---------	-------

**▲ ESTRADIOL,ULTRASENSITIVE, LC/MS****32 H** Reference Range: < OR = 29 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

**▲ PSA (FREE AND TOTAL)**

Analyte	Value
<b>PSA, TOTAL</b>	<b>1.3</b> Reference Range: < OR = 4.0 ng/mL
<b>PSA, FREE</b>	<b>0.3</b> ng/mL

**▲ PSA, % FREE****23 L** Reference Range: >25 % (calc)

PSA(ng/mL)	Free PSA(%)	Estimated(x) Probability of Cancer(as%)
0-2.5	(*)	Approx. 1
2.6-4.0(1)	0-27(2)	24(3)
4.1-10(4)	0-10	56
	11-15	28
	16-20	20
	21-25	16
	>or =26	8
>10(+)	N/A	>50

References:(1)Catalona et al.:Urology 60: 469-474 (2002)  
 (2)Catalona et al.:J.Urol 168: 922-925 (2002)  
 Free PSA(%) Sensitivity(%) Specificity(%)  
 < or = 25 85 19  
 < or = 30 93 9  
 (3)Catalona et al.:JAMA 277: 1452-1455 (1997)  
 (4)Catalona et al.:JAMA 279: 1542-1547 (1998)

(x)These estimates vary with age, ethnicity, family history and DRE results.

(\*)The diagnostic usefulness of % Free PSA has not been established in patients with total PSA below 2.6 ng/mL

(+)In men with PSA above 10 ng/mL, prostate cancer risk is determined by total PSA alone.

The Total PSA value from this assay system is standardized against the equimolar PSA standard. The test result will be approximately 20% higher when compared to the WHO-standardized Total PSA (Siemens assay). Comparison of serial PSA results should be interpreted with this fact in mind.

PSA was performed using the Beckman Coulter Immunoassay method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

**TESTOSTERONE, FREE (DIALYSIS) AND TOTAL,MS**

Analyte	Value
<b>TESTOSTERONE, TOTAL, MS</b>	<b>796</b> Reference Range: 250-1100 ng/dL

For additional information, please refer to <http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMSFAQ165>  
 (This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

---

**TESTOSTERONE, FREE****129.7**    Reference Range: 35.0-155.0 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

**Performing Sites**



AMD Quest Diagnostics/Nichols Chantilly-Chantilly VA, 14225 Newbrook Dr, Chantilly, VA 20151-2228 Laboratory Director: Patrick W Mason M.D.,PhD

EZ Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Laboratory Director: Irina Maramica MD,PhD,MBA

Z99 Quest Diagnostics-Clifton, 1 Insights Drive, Clifton, NJ 07012-2355 Laboratory Director: Peter E Fisher

---

**Key**

 Priority Out of Range     Out of Range

These results have been sent to the person who ordered the tests. Your receipt of these results should not be viewed as medical advice and is not meant to replace discussion with your doctor or other healthcare professional.

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - '®' and '™' - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2022 Quest Diagnostics Incorporated. All rights reserved.

